Elufor oral suspension 200mg/5ml bottle, 90ml

Composition

5 ml of suspension contains: Active ingredient:  Nifuroxazide 200.0 mgm Auxiliary substances:  sucrose 1000.0 mg, sodium hydroxide 2.0 mg, methyl parahydroxybenzoate 5.0 mg, ethanol 96% 0.05 ml, carbomer 10.5 mg, citric acid 0.75 mg, banana flavor 10.00 mg, water up to 5.0 ml

Pharmacological action

Broad-spectrum antimicrobial agent derived from 5-nitrofuran. It is assumed that the antimicrobial activity of nifuroxazide is caused by the presence of a NO2 group in its composition, which causes inhibition of dehydrogenase activity and disrupts protein synthesis in pathogenic bacteria. Active against gram-positive microorganisms (Streptococcus aureus, Staphylococcus pyogenes, Clostridium), Gram-negative enterobacteria (Escherichia coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter spp., Vibrio cholerae, Campylobacter jejuni, Edwarsiella, Citrobacter, Yersinia enterocolitica). Nifuroxazide has no effect on saprophytic flora and does not disturb the balance of normal intestinal flora. In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokineticsafter oral use, nifuroxazide is practically not absorbed from the digestive tract, and its antibacterial effect is exerted exclusively in the intestinal lumen. It is completely excreted through the gastrointestinal tract. The rate of elimination depends on both the dose of the drug and the motility of the intestinal tract.

Indications

Diarrhea of bacterial origin; Chronic lesions of the gastrointestinal tract of bacterial etiology, accompanied by dyspeptic phenomena.

Contraindications

Hypersensitivity to nitrofuran derivatives or other components of the drug;fructose intolerance; Glucose-galactose malabsorption syndrome, sucrose and isomaltase insufficiency;Neonatal period (up to 1 month), prematurity.

Side effects

Allergic reactions, nausea, vomiting.

How to take, course of use and dosage

It is applied inside.

For dosing, a dosage spoon with a volume of 5 ml is used, which has a graduation of 2.5 ml. The suspension should be shaken well before use. Children 1-6 months: 2.5 ml 2-3 times a day (with an interval of 8 to 12 hours). Children from 7 months to 2 years: 2.5 ml 4 times a day (with an interval of 8 hours). Children from 3 to 7 years: 5 ml 3 times a day (with an interval of 8 hours). Children over 7 years of age and adults: 5 ml 3-4 times a day (at intervals of 6-8 hours). Nifuroxazide therapy should not be continued for more than 7 days.

Overdose

The drug is not absorbed from the gastrointestinal tract and does not enter the systemic circulation. Symptoms of overdose are not known. If the dose is exceeded, gastric lavage and symptomatic treatment are recommended.

Special instructions

When treating diarrhea simultaneously with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be performed according to the patient’s condition and the intensity of diarrhea. The use of alcohol during nifuroxazide therapy is prohibited. Before prescribing the suspension to infants, it is necessary to exclude their congenital deficiency of sucrose-breaking enzymes.

Influence on the ability to drive vehicles and work with mechanisms

The drug does not affect psychomotor activity and the ability to drive vehicles and work with mechanisms.

Storage conditions

At a temperature of 15° to 30 °C. Keep out of reach of children. The opened bottle should be stored for no more than 7 days.

Shelf

life 3 yearsuse after the expiration date.

Active ingredient

Nifuroxazide

Dosage form

suspension for oral use

Description

For children as prescribed by a doctor, For adults

Indications

Poisoning, Salmonellosis, Diarrhea, Intestinal infections